These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 3047336)

  • 21. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group.
    J Clin Oncol; 1988 Apr; 6(4):679-88. PubMed ID: 2895801
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-dose ketoconazole in advanced hormone-refractory prostate cancer: endocrinologic and clinical effects.
    Trump DL; Havlin KH; Messing EM; Cummings KB; Lange PH; Jordan VC
    J Clin Oncol; 1989 Aug; 7(8):1093-8. PubMed ID: 2474059
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FAM chemotherapy +/- aminoglutethimide in the treatment of pancreatic carcinoma.
    Lipton A; Harvey HA; Santen RJ; Stryker JA; Barnes SG; Walker BK; Dixon RH; Givant EM; Bartholomew MJ; Nadjafi C
    Eur J Surg Oncol; 1990 Feb; 16(1):12-4. PubMed ID: 2307239
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer.
    Lin CC; Hsu CH; Chen J; Tsai TC; Cheng AL; Pu YS
    Anticancer Res; 2001; 21(2B):1385-90. PubMed ID: 11396219
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adrenal steroid levels in castrated men with prostatic carcinoma treated with aminoglutethimide plus hydrocortisone.
    Ahmann FR; Crawford ED; Kreis W; Levasseur Y
    Cancer Res; 1987 Sep; 47(17):4736-9. PubMed ID: 3621171
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma.
    Bennett JM; Muss HB; Doroshow JH; Wolff S; Krementz ET; Cartwright K; Dukart G; Reisman A; Schoch I
    J Clin Oncol; 1988 Oct; 6(10):1611-20. PubMed ID: 3049953
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cyclophosphamide versus 5-fluorouracil, doxorubicin, and mitomycin C (FAM') in the treatment of hormone-resistant metastatic carcinoma of the prostate: a preliminary report of a randomized trial.
    Kasimis BS; Miller JB; Kaneshiro CA; Forbes KA; Moran EM; Metter GE
    J Clin Oncol; 1985 Mar; 3(3):385-92. PubMed ID: 3838343
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens.
    Thall PF; Logothetis C; Pagliaro LC; Wen S; Brown MA; Williams D; Millikan RE
    J Natl Cancer Inst; 2007 Nov; 99(21):1613-22. PubMed ID: 17971530
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-hormone treatment for prostate cancer relapsing after treatment with flutamide and castration. Addition of aminoglutethimide and low dose hydrocortisone to combination therapy.
    Labrie F; Dupont A; Bélanger A; Cusan L; Brochu M; Turina E; Pinault S; Lacourciere Y; Emond J
    Br J Urol; 1989 Jun; 63(6):634-8. PubMed ID: 2752257
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281.
    Aisner J; Cirrincione C; Perloff M; Perry M; Budman D; Abrams J; Panasci L; Muss H; Citron M; Holland J
    J Clin Oncol; 1995 Jun; 13(6):1443-52. PubMed ID: 7751891
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.
    Tannock IF; Fizazi K; Ivanov S; Karlsson CT; Fléchon A; Skoneczna I; Orlandi F; Gravis G; Matveev V; Bavbek S; Gil T; Viana L; Arén O; Karyakin O; Elliott T; Birtle A; Magherini E; Hatteville L; Petrylak D; Tombal B; Rosenthal M;
    Lancet Oncol; 2013 Jul; 14(8):760-8. PubMed ID: 23742877
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02.
    Rosenthal SA; Bae K; Pienta KJ; Sobczak ML; Asbell SO; Rajan R; Kerlin KJ; Michalski JM; Sandler HM;
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):672-8. PubMed ID: 18990504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A trial of combination chemotherapy followed by hormonal therapy for previously untreated metastatic carcinoma of the prostate.
    Seifter EJ; Bunn PA; Cohen MH; Makuch RW; Dunnick NR; Javadpour N; Bensimon H; Eddy JL; Minna JD; Ihde DC
    J Clin Oncol; 1986 Sep; 4(9):1365-73. PubMed ID: 2943877
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment for hormone-refractory or relapsing prostatic cancer].
    Hirao Y; Ozono S; Okajima E
    Gan To Kagaku Ryoho; 1996 Mar; 23(4):418-26. PubMed ID: 8678492
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
    Pummer K; Lehnert M; Stettner H; Hubmer G
    Eur Urol; 1997; 32 Suppl 3():81-5. PubMed ID: 9267791
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Aminoglutethimide in the treatment of advanced prostatic cancer].
    Bauer HW; Schmeller NT; Schmiedt E
    Urologe A; 1985 Jan; 24(1):46-8. PubMed ID: 4039084
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term outcome for men with androgen independent prostate cancer treated with ketoconazole and hydrocortisone.
    Scholz M; Jennrich R; Strum S; Brosman S; Johnson H; Lam R
    J Urol; 2005 Jun; 173(6):1947-52. PubMed ID: 15879788
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Androgen suppression by hydrocortisone without aminoglutethimide in orchiectomised men with prostatic cancer.
    Plowman PN; Perry LA; Chard T
    Br J Urol; 1987 Mar; 59(3):255-7. PubMed ID: 3567487
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aminoglutethimide and estrogenic stimulation before chemotherapy for treatment of advanced breast cancer. Preliminary results of a phase II study conducted by the E.O.R.T.C. Breast Cancer Cooperative Group.
    Paridaens R; Van der Wijst JB; Julien JP; Clarysse A; Ferrazzi E; Rotmensz N; Heuson JC
    J Steroid Biochem; 1985 Dec; 23(6B):1181-3. PubMed ID: 3912624
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized trial of combination chemotherapy in hormone-resistant metastatic prostate carcinoma.
    Page JP; Levi JA; Woods RL; Tattersall MN; Fox RM; Coates AS
    Cancer Treat Rep; 1985 Jan; 69(1):105-7. PubMed ID: 3881176
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.